17635-44-8

Basic information

• Product Name: 3,4,5-Tribromopyrazole
• Synonyms: 3,4,5-TRIBROMOPYRAZOLE;3,4,5-TRIBROMO-1H-PYRAZOLE;3,4,5-Tribromopyrazole, 97+%;3,4,5-Tribromopyrazol;3,4,5-TribroMo-1H-pyrazole, 97%, 97%
• CAS NO: 17635-44-8
• Molecular Formula: C₃HBr₃N₂
• Molecular Weight: 304.77
• Product Categories: Heterocyclic Compounds;Heterocycles;Piperidines
• Mol File: 17635-44-8.mol
• Article Data: 12

Chemical Properties

• Melting Point: 190-192°C
• Boiling Point: 381.5 °C at 760 mmHg
• Flash Point: 184.5 °C
• Appearance: Off-white solid
• Density: 2.782 g/cm₃
• Vapor Pressure: 1.11E-05mmHg at 25°C
• Refractive Index: 1.689
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform, Methanol
• PKA: 6.47±0.50(Predicted)
• Water Solubility: Insoluble in water. Soluble in Chloroform.
• BRN: 113501
• CAS DataBase Reference: 3,4,5-Tribromopyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4,5-Tribromopyrazole(17635-44-8)
• EPA Substance Registry System: 3,4,5-Tribromopyrazole(17635-44-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37
• Hazardous Substances Data: 17635-44-8(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 17635-44-8 differently. You can refer to the following data:
1. 3,4,5-Tribromopyrazole is used in the preparation of 1-aryl-4-substituted piperazine CCR1 antagonists for the treatment of inflammation and immune disorders.
2. 2,4,5-Tribromoimidazole(2,4,5-TBI) on condensation with sugar precursors yields 2,4,5-TBI nucleosides. It is an important raw material and intermediate used in organic synthesis, pharmaceuticals, agrochemicals and dyestuff.

InChI:InChI=1/C3HBr3N2/c4-1-2(5)7-8-3(1)6/h(H,7,8)

Upstream product

• 104599-40-8 1-nitro-3,4,5-tribromo-1H-pyrazole 
• 71-43-2 benzene 
• 1621-91-6 1H-pyrazole-3-carboxylic acid 
• 288-13-1 NH-pyrazole 
• 923035-87-4 1-vinyl-3,4,5-tribromo-1H-pyrazole 
• 5932-18-3 3,4-dibromo-1H-pyrazole 

Downstream Products

• 98136-32-4 1-acetyl-3,4,5-tribromo-1H-pyrazole 
• 104599-40-8 1-nitro-3,4,5-tribromo-1H-pyrazole 
• 90767-31-0 1-benzyl-3,4,5-tribromo-1H-pyrazole 
• 104599-37-3 3,4-dibromo-5-nitro-1H-pyrazole 
• 67460-86-0 3,5-dibromo-1H-pyrazole 
• 1347628-00-5 8,9-dibromo-12-(4-methoxyphenyl)-12H-naphtho[1,2-e]pyrazolo[5,1-b][1,3]oxazine 
• 1262050-71-4 4-bromo-2-(3,4,5-tribromo-1H-1-pyrazolylmethyl)phenol 
• 1262050-70-3 2-(3,4,5-tribromo-1H-1-pyrazolylmethyl)phenol 
• 104599-36-2 3,5-dibromo-4-nitro-1H-pyrazole 
• 34157-45-4 2-(3,4,5-tribromo-pyrazol-1-yl)-propionic acid 

Relevant articles and documents

The N-vinyl group as a protection group of the preparation of 3(5)-substituted pyrazoles via bromine-lithium exchange

Treatment of 3,4,5-tribromopyrazole with 1,2-dibromoethane and triethylamine gave 3,4,5-tribromo-1-vinylpyrazole, which underwent regioselective bromine-lithium exchange at the 5-position. Subsequent addition of an electrophile gave 5-substituted 3,4-dibr

METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID

Described herein are novel methods of synthesizing 5-Bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives. Also described herein are novel reaction intermediates.

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

The underlying cause of spinal muscular atrophy (SMA) is a deficiency of the survival motor neuron (SMN) protein. Starting from hits identified in a high-throughput screening campaign and through structure-activity relationship investigations, we have developed small molecules that potently shift the alternative splicing of the SMN2 exon 7, resulting in increased production of the full-length SMN mRNA and protein. Three novel chemical series, represented by compounds 9, 14, and 20, have been optimized to increase the level of SMN protein by >50% in SMA patient-derived fibroblasts at concentrations of 160 nM. Daily administration of these compounds to severe SMA Δ7 mice results in an increased production of SMN protein in disease-relevant tissues and a significant increase in median survival time in a dose-dependent manner. Our work supports the development of an orally administered small molecule for the treatment of patients with SMA.